Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2025-01-31 Proxy Solicitation & In…
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
As per letter attached
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Meeting of Preference Shareholders convened pursuant to an order of the National Company Law Tribunal (NCLT) for approval of a Scheme of Amalgamation between Lyka Exports Limited and Lyka Labs Limited. It includes details about the meeting date, mode (video conferencing), voting procedures, and references to various annexures including financial statements and reports related to the merger. The document is primarily a notice to shareholders to approve a merger scheme, not the merger scheme itself or the financial statements. It also includes procedural details about voting and the role of the tribunal and regulatory bodies. This fits the definition of Proxy Solicitation & Information Statement (PSI), as it is material sent to shareholders to provide information and request votes for a meeting regarding a corporate action (amalgamation). It is not an Annual Report, Audit Report, or a direct M&A filing but a solicitation for shareholder approval of the merger scheme. Therefore, the correct classification is PSI with high confidence.
2025-01-31 English
As per letter attached
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Meeting of Equity Shareholders convened pursuant to an order of the National Company Law Tribunal (NCLT) for approval of a Scheme of Amalgamation between two companies. It includes details about the meeting date, mode (video conferencing), remote e-voting, and e-voting procedures. The document also contains an index listing annexures such as the Scheme of Amalgamation, explanatory statements, reports from committees, valuation reports, audited and unaudited financial statements, and shareholding patterns. The primary purpose is to notify shareholders about the meeting to approve the merger scheme and provide related information. This is not the merger filing itself, nor the voting results, but a formal notice convening the meeting and providing materials for shareholder consideration. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings, especially in the context of mergers and amalgamations.
2025-01-31 English
As per letter attached
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the dispatch of notices for shareholders' and creditors' meetings as per an order from the National Company Law Tribunal (NCLT). It mentions the schedule for meetings to approve a Scheme of Amalgamation and details about e-voting timelines. The document is short (2399 characters) and serves as an announcement of the dispatch of notices for meetings rather than the meeting materials themselves or the results. It does not contain financial statements or detailed reports. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement related to corporate actions and compliance with legal orders, not a full report or a voting result announcement.
2025-01-31 English
Updates
Regulatory Filings
2025-01-24 English
As per attached letter
Regulatory Filings
2025-01-24 English
As per letter attached
Regulatory Filings Classification · 95% confidence The document is a quarterly compliance report on corporate governance submitted by a listed entity, Lyka Labs Limited, for the quarter ending 31st December 2024. It includes detailed information on the composition of the board of directors, committees, meetings held, investor grievance redressal, disclosures on acquisition of shares or voting rights in unlisted companies, imposition of fines or penalties, and updates on ongoing tax litigations or disputes. The content is regulatory in nature, focusing on governance compliance and disclosures required by SEBI (Listing obligations and disclosure requirements) Regulations, 2015. It is a structured quarterly filing with substantive governance and compliance data rather than a full annual report or a simple announcement. This fits the category of Regulatory Filings (RNS) as it is a general regulatory compliance document that does not fit into more specific categories like Annual Report, Interim Report, or Management Reports. The document length and detail also confirm it is not a brief announcement or certification but a comprehensive regulatory filing.
2025-01-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.